About this trial
This clinical trial tests the impact of tear fluid in detecting tumor-associated extracellular vesicles (TEVs) in patients with glioblastoma. Brain tumors release small particles, called TEVs, that may provide information about the tumor, including how it responds to treatment. These particles can be found in cerebrospinal fluid (CSF), which is the fluid that surrounds the brain and spinal cord. Collecting CSF can be difficult and expensive, especially if samples are needed frequently to track these particles over time. Tear fluid is easier to collect than spinal fluid. If tears are found to contain similar tumor-related particles, changes in the tumor may be tracked by studying the particles found in tear fluid.
Eligibility criteria
Qualifiers
Adults (age ≥ 18)
Male and female
All racial and ethnic groups
Pathologically-proven diagnosis of GBM or healthy volunteers
Disqualifiers
Active ocular infection or inflammation
Recent ocular surgery (within 3 months)
Chronic dry eyes
Known allergy or hypersensitivity to topical anesthetics
Trial design
Treatments tested in this trial
- Biospecimen Collection
- Biospecimen Collection
- Electronic Health Record Review
- Questionnaire Administration
Treatment groups
Sponsors and collaborators
City of Hope Medical Center
Lead sponsor
National Cancer Institute (NCI)
Collaborator